公开(公告)号：US11485741B2

公开(公告)日：2022-11-01

申请号：US17043886

申请日：2019-04-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ashok V. Purandare ,  Honghe Wan ,  Liqi He ,  Sanjeev Gangwar ,  Shoshana L. Posy ,  Yam B. Poudel ,  Prasanna Sivaprakasam ,  Naidu S. Chowdari

IPC: C07D487/16 ,  A61K47/60

Abstract: Compounds having a structure according to formula are modulators of TLR7 activity and can be used to treat conditions amenable to treatment by the modulation of TLR7 activity.

公开(公告)号：US20220306630A1

公开(公告)日：2022-09-29

申请号：US17632909

申请日：2020-08-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Lalgudi S. Harikrishnan ,  Peter Kinam Park ,  Zheming Ruan ,  Donna D. Wei ,  Daniel O'Malley ,  Honghe Wan ,  Ashok Vinayak Purandare ,  Brian E. Fink

IPC: C07D471/10 ,  C07C317/18 ,  C07D213/73 ,  C07D213/71 ,  C07C255/60 ,  C07D213/82 ,  C07D231/12 ,  C07D231/18 ,  C07D263/24 ,  C07D213/56 ,  C07D401/12 ,  C07C311/16 ,  C07D213/69 ,  C07D233/61 ,  C07D211/34 ,  C07D235/18 ,  C07D213/58 ,  C07D211/96 ,  C07D295/26

Abstract: The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US20160108050A1

公开(公告)日：2016-04-21

申请号：US14976476

申请日：2015-12-21

Applicant: Bristol-Myers Squibb Company

Inventor： Ashok Vinayak Purandare ,  Brian E. Fink ,  Walter Lewis Johnson ,  Amy C. Hart ,  Liqi He ,  Tram N. Huynh ,  Jennifer lnghrim ,  Harold Mastalerz ,  Xiaopeng Sang ,  Christine M. Tarby ,  Honghe Wan ,  Wayne Vaccaro ,  Guifen Zhang ,  Yufen Zhao ,  Kurt Zimmermann ,  Yong Zhang ,  Libing Chen ,  Bin Chen ,  John S. Tokarski ,  Ashvinikumar V. Gavai

IPC: C07D487/04 ,  C07F9/6561 ,  C07F7/18 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61K31/675 ,  A61K45/06 ,  C07D471/10 ,  C07D487/08 ,  C07D487/10 ,  C07D487/22 ,  C07D498/04 ,  C07D519/00 ,  C07F7/1804 ,  C07F9/6521 ,  C07F9/6561 ,  C07F9/65616

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

公开(公告)号：US10550125B2

公开(公告)日：2020-02-04

申请号：US15769113

申请日：2016-10-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ashok Vinayak Purandare ,  Kurt Zimmermann ,  Honghe Wan

IPC: A61K31/53 ,  C07D487/04 ,  A61P19/02 ,  A61P17/06 ,  A61P35/02

Abstract: The invention provides pharmaceutically active compounds of formula (I) and prodrugs thereof. The formula (I) 2-(aminophenylamino)-4-amino-7-cyano-imidazo[2,1-f][1,2,4]triazine derivatives inhibit CK2 protein kinase activity, thereby making them useful for treating cancer, psoriasis and rheumatoid arthritis.

公开(公告)号：US20150210697A1

公开(公告)日：2015-07-30

申请号：US14414152

申请日：2013-07-12

Applicant: Bristol-Myers Squibb Company

Inventor： Ashok Vinayak Purandare ,  Brian E. Fink ,  Walter Lewis Johnson ,  Amy C. Hart ,  Liqi He ,  Tram N. Huynh ,  Jennifer Inghrim ,  Harold Mastalerz ,  Xiaopeng Sang ,  Christine M. Tarby ,  Honghe Wan ,  Wayne Vaccaro ,  Guifen Zhang ,  Yufen Zhao ,  Kurt Zimmermann ,  Yong Zhang ,  Libing Chen ,  Bin Chen ,  John S. Tokarski ,  Ashvinikumar V. Gavai

IPC: C07D487/04 ,  C07F7/18 ,  C07D487/10 ,  C07D487/08 ,  C07D471/10

CPC classification number: C07D487/04 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61K31/675 ,  A61K45/06 ,  C07D471/10 ,  C07D487/08 ,  C07D487/10 ,  C07D487/22 ,  C07D498/04 ,  C07D519/00 ,  C07F7/1804 ,  C07F9/6521 ,  C07F9/6561 ,  C07F9/65616

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

公开(公告)号：US08940736B2

公开(公告)日：2015-01-27

申请号：US13940619

申请日：2013-07-12

Applicant: Bristol-Myers Squibb Company

Inventor： Ashok Vinayak Purandare ,  Brian E. Fink ,  Ashvinikumar V. Gavai ,  Walter Lewis Johnson ,  Amy C. Hart ,  Liqi He ,  Tram N. Huynh ,  Jennifer Inghrim ,  Harold Mastalerz ,  Xiaopeng Sang ,  Christine M. Tarby ,  Honghe Wan ,  Wayne Vaccaro ,  Guifen Zhang ,  Yufen Zhao ,  Kurt Zimmermann

IPC: A61K31/535 ,  A01N43/00 ,  A61K31/00 ,  A01N57/00 ,  A61K31/675 ,  C07D413/00 ,  C07D487/00 ,  C07D243/08 ,  A61K31/53 ,  A61K45/06 ,  A61K31/5377 ,  C07D471/10 ,  C07D487/10 ,  C07D498/04 ,  A61K31/551 ,  C07D487/04 ,  A61K31/5383 ,  C07F9/6521

CPC classification number: C07D487/04 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61K31/675 ,  A61K45/06 ,  C07D471/10 ,  C07D487/08 ,  C07D487/10 ,  C07D487/22 ,  C07D498/04 ,  C07D519/00 ,  C07F7/1804 ,  C07F9/6521 ,  C07F9/6561 ,  C07F9/65616

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐。 式（I）咪唑三嗪抑制蛋白激酶活性，从而使它们用作抗癌剂。

公开(公告)号：US20140018319A1

公开(公告)日：2014-01-16

申请号：US13940619

申请日：2013-07-12

Applicant: Bristol-Myers Squibb Company

Inventor： Ashok Vinayak Purandare ,  Brian E. Fink ,  Ashvinikumar V. Gavai ,  Walter Lewis Johnson ,  Amy C. Hart ,  Liqi He ,  Tram N. Huynh ,  Jennifer Inghrim ,  Harold Mastalerz ,  Xiaopeng Sang ,  Christine M. Tarby ,  Honghe Wan ,  Wayne Vaccaro ,  Guifen Zhang ,  Yufen Zhao ,  Kurt Zimmermann

IPC: A61K31/675 ,  A61K31/53 ,  A61K31/551 ,  A61K31/5377 ,  C07D487/10 ,  C07F9/6521 ,  C07D498/04 ,  A61K31/5383 ,  A61K45/06 ,  C07D487/04 ,  C07D471/10

CPC classification number: C07D487/04 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61K31/675 ,  A61K45/06 ,  C07D471/10 ,  C07D487/08 ,  C07D487/10 ,  C07D487/22 ,  C07D498/04 ,  C07D519/00 ,  C07F7/1804 ,  C07F9/6521 ,  C07F9/6561 ,  C07F9/65616

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐。 式（I）咪唑三嗪抑制蛋白激酶活性，从而使它们用作抗癌剂。

公开(公告)号：US20230295087A1

公开(公告)日：2023-09-21

申请号：US17610634

申请日：2020-05-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Lalgudi S. Harikrishnan ,  Brian E. Fink ,  Patrice Gill ,  Lan-Ying Qin ,  Muthoni G. Kamau ,  Tram N. Huynh ,  Ashok Vinayak Purandare ,  Honghe Wan ,  Daniel O’Malley

IPC: C07D209/60 ,  C07D409/06 ,  C07F5/02 ,  C07D403/06 ,  C07D403/10 ,  C07D401/06 ,  C07D417/06 ,  C07D413/06 ,  C07D405/12 ,  C07D403/12 ,  C07D409/12

CPC classification number: C07D209/60 ,  C07D401/06 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/12 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07F5/025 ,  C07B2200/05

Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US20180305364A1

公开(公告)日：2018-10-25

申请号：US15769113

申请日：2016-10-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ashok Vinayak Purandare ,  Kurt Zimmermann ,  Honghe Wan

IPC: C07D487/04 ,  A61P35/02 ,  A61P17/06 ,  A61P19/02

CPC classification number: C07D487/04 ,  A61P17/06 ,  A61P19/02 ,  A61P35/02

Abstract: PRODRUGS OF IMIDAZOTRIAZINE COMPOUNDS AS CK2 INHIBITORS The invention provides pharmaceutically active compounds of formula (I) and prodrugs thereof. The formula (I) 2-(aminophenylamino)-4-amino-7-cyano-imidazo[2,1-f][1,2,4]triazine derivatives inhibit CK2 protein kinase activity, thereby making them useful for treating cancer, psoriasis and rheumatoid arthritis.

公开(公告)号：US09593116B2

公开(公告)日：2017-03-14

申请号：US14892622

申请日：2014-05-28

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ashok Vinayak Purandare ,  Honghe Wan

IPC: C07D471/14

CPC classification number: C07D471/14

Abstract: Crystalline form, Form T1H1.5-4, of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl -1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide (Compound (I)) is provided. Also provided is a pharmaceutical composition and an oral dosage form comprising Form T1H1.5-4 of Compound (I) as well as a method of using the Form T1H1.5-4 of Compound for the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis.

Abstract translation: N，N-二环丙基-4-（1,5-二甲基-1H-吡唑-3-基氨基）-6-乙基-1-甲基-1,6-二氢咪唑并〔4〕的晶型T1H1.5-4 ，5-d]吡咯并[2,3-b]吡啶-7-甲酰胺（化合物（I））。 还提供了包含化合物（I）的T1H1.5-4形式的药物组合物和口服剂型，以及使用化合物形式T1H1.5-4用于治疗骨髓增生性疾病的方法，其包括多血红素血症 ，血小板减少症和原发性骨髓纤维化。